Apogee Therapeutics, Inc. has successfully completed enrollment ahead of schedule in Part A of its Phase 2 APEX clinical trial for its treatment APG777, which targets moderate-to-severe atopic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results